Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12605189 | 1.00 | HSD17B10 (0.40) | HSD17B10ALDH1A1TSHRMAPTKMT2A | |
| SCHEMBL7039511 | 0.91 | HSD17B10 (0.47) | HSD17B10ALDH1A1TSHRMAPTKMT2A | |
| SCHEMBL27329590 | 0.91 | HSD17B10 (0.47) | HSD17B10ALDH1A1TSHRMAPTKMT2A | |
| SCHEMBL3974583 | 0.91 | HSD17B10 (0.47) | HSD17B10ALDH1A1TSHRMAPTKMT2A | |
| SCHEMBL5059158 | 0.91 | HSD17B10 (0.47) | HSD17B10ALDH1A1TSHRMAPTKMT2A | |
| SCHEMBL6424182 | 0.91 | HSD17B10 (0.47) | HSD17B10ALDH1A1TSHRMAPTKMT2A | |
| SCHEMBL18537917 | 0.86 | HSD17B10 (0.40) | HSD17B10ALDH1A1TSHRMAPTKMT2A | |
| SCHEMBL18537914 | 0.86 | HSD17B10 (0.40) | HSD17B10ALDH1A1TSHRMAPTKMT2A | |
| SCHEMBL22821626 | 0.86 | HSD17B10 (0.40) | HSD17B10ALDH1A1TSHRMAPTKMT2A | |
| SCHEMBL18537936 | 0.86 | HSD17B10 (0.40) | HSD17B10ALDH1A1TSHRMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140178302-A1 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING S.P.A. (IT) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140178302-A1 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | ITGA2B, ITGB2, ITGB1 | HSD17B10 4649/4885ALDH1A1 3450/4885TSHR 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.